EGFR and pachyonychia congenita: Targeted therapy drugs for PC include small molecule tyrosine kinase inhibitor (TKI) erlotinib targeting epidermal growth factor receptor (EGFR), oral mammalian target of rapamycin (mTOR) inhibitor everolimus and small molecule multi-target receptor TKI sunitinib which targets RTK.